A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia

Journal of Microbiology, Immunology and Infection

Volumn 50, Issue 6, 2017, Pages 811-820

  Liu, Yang ^a,b   Zhang, Yingyuan ^a,b   Wu, Jufang ^a,b   Zhu, Demei ^a,b   Sun, Shenghua ^c   Zhao, Li ^d   Wang, Xuefeng ^e   Liu, Hua ^f   Ren, Zhenyi ^g   Wang, Changzheng ^h   Xiu, Qingyu ⁱ   Xiao, Zuke ^j   Cao, Zhaolong ^k   Cui, Shehuai ^l   Yang, Heping ^h   Liang, Yongjie ^m   Chen, Ping ⁿ   Lv, Yuan ^o   Hu, Chengping ^p   Lv, Xiaoju ^q   Liu, Shuang ^r   Kuang, Jiulong ^s   Li, Jianguo ^t   Wang, Dexi ^u   Chang, Liwen ^v   more..

^a FUDAN UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d CHINA MEDICAL UNIVERSITY   (China)

^e ZHEJIANG UNIVERSITY   (China)

^f GANSU PROVINCIAL HOSPITAL   (China)

^g HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^h THIRD MILITARY MEDICAL UNIVERSITY   (China)

ⁱ SECOND MILITARY MEDICAL UNIVERSITY   (China)

^j Jiangxi Provincial People's Hospital   (China)

^k PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^l THIRD MILITARY MEDICAL UNIVERSITY   (China)

^m TONGJI UNIVERSITY   (China)

ⁿ GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^o PEKING UNIVERSITY FIRST HOSPITAL   (China)

^p CENTRAL SOUTH UNIVERSITY   (China)

^q SICHUAN UNIVERSITY   (China)

^r CAPITAL MEDICAL UNIVERSITY   (China)

^s NANCHANG UNIVERSITY   (China)

^t SUN YAT SEN UNIVERSITY   (China)

^u GUANGZHOU RED CROSS HOSPITAL   (China)

^v TaiGen Biotechnology Co Ltd   (Taiwan)

more..

Author keywords

clinical trial; community acquired pneumonia; efficacy; nenomoxacin; safety

Indexed keywords

ALANINE AMINOTRANSFERASE; LEVOFLOXACIN; NEMONOXACIN; PLACEBO; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL; FEMALE; HEART BUNDLE BRANCH BLOCK; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PROTEIN URINE LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMMUNITY ACQUIRED INFECTION; COMPARATIVE STUDY; DRUG EFFECT; HAEMOPHILUS INFLUENZAE; MICROBIOLOGY; MIDDLE AGED; MYCOPLASMA PNEUMONIAE; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HAEMOPHILUS INFLUENZAE; HUMANS; LEVOFLOXACIN; MALE; MIDDLE AGED; MYCOPLASMA PNEUMONIAE; PNEUMONIA, BACTERIAL; QUINOLONES; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84951951339     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2015.09.005     Document Type: Article

References (17)

1. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
2. Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., et al., Infectious Diseases Society of America; American Thoracic Society, Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44:Suppl. 2 (2007), S27–72.
3. Peto, L., Nadjm, B., Horby, P., Ngan, T.T., van Doorn, R., Van Kinh, N., et al. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Trans R Soc Trop Med Hyg 108 (2014), 326–337.
4. Woodhead, M., Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl 36 (2002), 20s–27s.
5. Hu, F.P., Zhu, D.M., Wang, F., Guo, Y., Yang, Y., Jiang, X.F., et al. CHINET 2013 surveillance of bacterial resistance in China. Chin J Infect Chemother 14 (2014), 369–378.
6. Guo, B., Wu, X., Zhang, Y., Shi, Y., Yu, J., Cao, G., et al. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin Drug Investig 32 (2012), 475–486.
7. Adam, H.J., Laing, N.M., King, C.R., Lulashnyk, B., Hoban, D.J., Zhanel, G.G., In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother 53 (2009), 4915–4920.
8. Chen, Y.H., Liu, C.Y., Lu, J.J., King, C.H., Hsueh, P.R., In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J Antimicrob Chemother 64 (2009), 1226–1229.
9. Chen, Y.H., Liu, C.Y., Ko, W.C., Liao, C.H., Lu, P.L., Huang, C.H., et al. Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006–2010. Eur J Clin Microbiol Infect Dis 33 (2014), 233–239.
10. Lai, C.C., Tan, C.K., Lin, S.H., Liao, C.H., Chou, C.H., Hsu, H.L., et al. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J Antimicrob Chemother 64 (2009), 73–78.
11. Lauderdale, T.L., Shiau, Y.R., Lai, J.F., Chen, H.C., King, C.H., Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother 54 (2010), 1338–1342.
12. Li, C.R., Li, Y., Li, G.Q., Yang, X.Y., Zhang, W.X., Lou, R.H., et al. In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. J Antimicrob Chemother 65 (2010), 2411–2415.
13. Chung, D.T., Tsai, C.Y., Chen, S.J., Chang, L.W., King, C.H., Hsu, C.H., et al. Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother 54 (2010), 411–417.
14. Lin, L., Chang, L.W., Tsai, C.Y., Hsu, C.H., Chung, D.T., Aronstein, W.S., et al. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob Agents Chemother 54 (2010), 405–410.
15. Van Rensburg, D.J., Perng, R.P., Mitha, I.H., Bester, A.J., Kasumba, J., Wu, R.G., et al. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother 54 (2010), 4098–4106.
16. Lai, C.C., Lee, K.Y., Lin, S.W., Chen, Y.H., Kuo, H.Y., Hung, C.C., et al. Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther 12 (2014), 401–417.
17. Poole, R.M., Nemonoxacin: first global approval. Drugs 74 (2014), 1445–1453.